摘要
目的评价舒肝解郁胶囊治疗抑郁障碍的经济性。方法构建为期1年的抑郁障碍决策树模型和采用成本-效用分析评价舒肝解郁胶囊治疗原发性抑郁障碍的经济性,采用单因素和概率敏感性分析结果的稳定性。结果 1年期间,西酞普兰的成本为2718.84元,帕罗西汀为3126.60元,舍曲林为3862.21元,舒肝解郁为4031.20元,氟西汀为4234.12元;西酞普兰获得的QALYs为0.7211,帕罗西汀为0.7032,舍曲林为0.7217,舒肝解郁胶囊为0.7138,氟西汀为0.7136。以2016年3倍人均GDP作为阈值,最终经济性的判断依次为西酞普兰、舍曲林、舒肝解郁、氟西汀、帕罗西汀;单因素敏感性分析不影响研究结论,概率敏感性分析影响研究结果判断。结论舒肝解郁胶囊的经济性优于氟西汀和帕罗西汀,值得指南和临床推广。
Objective To evaluate economy of Shugan Jieyu Capsule in the treatment of depression.Methods To construct 1 year decision tree model of depressive disorder and to evaluate the economy of Shuganjieyu capsule in the treatment of primary depressive disorder by cost-utility analysis.The one-way sensitivity analysis and probabilistic sensitivity analysis were used to determine the stability of the basic analysis.Results The cost of Citalopram is 2718.84 yuan,Paroxetine is 3126.60 yuan,Sertraline is 3862.21 yuan,Shugan Jieyu capsule is 4031.20 yuan, Fluoxetine is 4234.12 yuan;Citalopram obtained 0.7211 QALYs,Paroxetine is 0.7032,Sertraline is 0.7217,Shugan Jieyu capsule is 0.7138,Fluoxetine is 0.7136.The one-way sensitivity analysis do not affect the conclusion of the study,and the probability of sensitivity is determined by the three-fold per capita GDP as the threshold,and the final economic judgment was Citalopram,Sertraline, Shugan Jieyu capsule,Fluoxetine and Paroxetine Analysis of the impact of research results to determine.Conclusion Economy of Shugan Jieyu capsule is better than fluoxetine and paroxetine,The safety of Shugan Jieyu capsule is less than four kinds of chemicals,Shugan Jieyu capsule is worthy of guidance and clinical application to promote.
出处
《中国药物经济学》
2017年第9期7-12,共6页
China Journal of Pharmaceutical Economics
